载药微球-TACE治疗难治性妇科恶性肿瘤肝转移12例

Drug-eluting beads-TACE for the treatment of refractory liver metastases from synecological malignant tumors: preliminary results in 12 patients

目的探索载药微球(DEB)-TACE治疗难治性妇科恶性肿瘤肝转移患者的安全性及短期疗效。方法回顾性分析我院收治的难治性妇科恶性肿瘤肝转移患者12例,给予DEB-TACE治疗肝转移病灶,观察首次治疗后不良反应情况,采用改良实体瘤疗效评价标准评估治疗后3个月及6个月的疗效。结果常见不良反应为细胞毒性反应、肝功一过性升高、发热、恶心呕吐及腹痛,不良反应集中在3级以下,无严重不良反应及与手术相关的死亡病例;术后3个月及6个月总缓解率(ORR)分别为75%,50%,疾病控制率(DCR)分别为91.7%,83.3%。结论 DEB-TACE治疗妇科恶性肿瘤肝转移患者安全,有效,值得临床进一步推广。

Objective To explore the safety and short-term efficacy of drug-eluting beads transcatheter arterial chemoembolization(DEB-TACE) in the treatment of refractory liver metastases from gynecological malignant tumors. Methods The clinical data of a total of 12 admitted patients with refractory liver metastasis from gynecological malignant tumor were retrospectively analyzed. All patients received DEB-TACE therapy. The adverse reactions after initial DEB-TACE treatment were recorded. The post-TACE3-month and 6-month curative effects were evaluated by modified solid tumor curative effect evaluation standard.Results The common adverse reactions included cytotoxic reaction, transient increase of liver function indexes, fever, nausea and vomiting, and abdominal pain. The severity of most adverse reactions was below level 3. No serious adverse reactions or procedure-related death occurred. The post-TACE 3-month overall remission rate(ORR) and 6-month ORR were 75% and 50% respectively, and the post-TACE 3-month and 6-month disease control rates were 91.7% and 83.3% respectively. Conclusion For the treatment of refractory liver metastases from gynecological malignant tumors, DEB-TACE is safe and effective. Therefore,this therapy is worthy of further clinical promotion.